Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biogen Inc.

NASDAQ: BIIB · Life Sciences · 2 alerts · CIK 875045

Share price
$251.65Close, Nov 16
Market cap
$37.2B
Shares outstanding
147.82MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biogen Inc. filings on SEC EDGAR ↗

6:08 AM ET 8-K
Financial Results

Biogen Financial Results

Biogen reported third quarter 2026 total revenue of $2.8 billion, an 11% increase year-over-year, driven by a 49% surge in its Growth Portfolio which now represents 63% of core pharmaceutical revenue. The results include the first full quarter of contribution from the acquired Apellis products and strong performance from SPINRAZA and LEQEMBI.

Term
Q3 2026

“Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products.”

Christopher A. Viehbacher, President and Chief Executive Officer

“With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders.”

Christopher A. Viehbacher, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.